DekaBank Deutsche Girozentrale Buys Shares of 130,000 Caribou Biosciences, Inc. (NASDAQ:CRBU)

DekaBank Deutsche Girozentrale bought a new stake in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 130,000 shares of the company’s stock, valued at approximately $764,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Charles Schwab Investment Management Inc. increased its stake in shares of Caribou Biosciences by 0.5% during the second quarter. Charles Schwab Investment Management Inc. now owns 412,625 shares of the company’s stock valued at $1,754,000 after purchasing an additional 2,176 shares in the last quarter. Rhumbline Advisers increased its position in shares of Caribou Biosciences by 2.6% during the first quarter. Rhumbline Advisers now owns 87,473 shares of the company’s stock valued at $464,000 after acquiring an additional 2,255 shares in the last quarter. Stansberry Asset Management LLC increased its position in shares of Caribou Biosciences by 3.5% during the fourth quarter. Stansberry Asset Management LLC now owns 70,004 shares of the company’s stock valued at $440,000 after acquiring an additional 2,342 shares in the last quarter. Credit Suisse AG increased its position in shares of Caribou Biosciences by 7.2% during the third quarter. Credit Suisse AG now owns 34,996 shares of the company’s stock valued at $368,000 after acquiring an additional 2,360 shares in the last quarter. Finally, Ameritas Investment Partners Inc. increased its position in shares of Caribou Biosciences by 168.4% during the first quarter. Ameritas Investment Partners Inc. now owns 3,945 shares of the company’s stock valued at $36,000 after acquiring an additional 2,475 shares in the last quarter. Institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Stock Down 3.1 %

Shares of CRBU opened at $4.07 on Tuesday. Caribou Biosciences, Inc. has a twelve month low of $3.44 and a twelve month high of $8.59. The firm has a 50 day moving average of $6.05 and a 200 day moving average of $5.47. The company has a market capitalization of $367.60 million, a P/E ratio of -2.81 and a beta of 2.48.

Caribou Biosciences (NASDAQ:CRBU) last issued its earnings results on Monday, March 11th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.17). Caribou Biosciences had a negative return on equity of 31.06% and a negative net margin of 296.05%. The company had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $5.17 million. On average, sell-side analysts expect that Caribou Biosciences, Inc. will post -1.76 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright raised their price target on shares of Caribou Biosciences from $23.00 to $24.00 and gave the company a “buy” rating in a research report on Tuesday, March 19th.

Caribou Biosciences Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.